This study used a cross-sectional design to investigate relationships among serum insulin-like growth factor (IGF) parameters (total serum IGF-I, IGF-II, and IGF-binding protein-3), serum estradiol, and bone mineral density (BMD) stratified for potential confounders, and a longitudinal design to investigate the effects of hormonal replacement therapy (HRT) on IGFs and BMD.
B ONE MINERAL density (BMD) declines in both sexes
with increasing age (1) , and in women, accelerated bone loss is observed around the menopause (1) . A complex interaction exists among age, bone mineral, and insulin-like growth factors (IGFs) (2) (3) (4) . This interaction has been demonstrated on the cellular or serum level in vitro (2) , on the tissue level in vitro (4) , and on the whole organism level in vivo (3, 5, 6) . IGF-I and IGF-II are potent regulators of osteoblast proliferation and differentiation in cellular models in vitro (2) , and serum IGF-I declines with age in vivo (3, 4) , possibly mediated by the age-related decrease in GH secretion (4, 7) . IGF-I is produced in the liver (8) in amounts that exceed those produced in the bone, and it has been reported by O'Sullivan and Ho (9) that transdermal estrogen inhibits the IGF system less than oral estrogen, the latter undergoing first pass metabolism in the liver.
The interaction among estrogen, endogenous GH production, serum IGFs, and bone mineral is not fully elucidated (10) . The accelerated perimenopausal bone loss is induced by the loss of endogenous estrogen production (1) . An acute increase in circulating IGF-I and IGF-II has also been observed in premenopausal women who were made estrogen deficient through administration of GnRH agonists (11) . Estrogen has a stimulatory effect on GH secretion, but decreases in endogenous GH production have been reported during short term estrogen administration in children (10) . In ovariectomized and estrogen-treated rats, circulating IGF-I correlates to cortical bone mass (12) . In accordance with this, positive correlations have been found between serum IGF-I and forearm BMD in perimenopausal women (6) as well as in osteoporotic patients (5) . Sugimoto et al. (5) also observed significantly lower serum values of IGF-I and IGFbinding protein-3 (IGFBP-3) in patients with osteoporotic spinal fractures than in control subjects. No correlation was found between IGFBP-2 and -3 and forearm BMD in perimenopausal women (6), whereas a positive correlation was observed between IGFBP-3 and forearm BMD in osteoporotic patients (5) . Furthermore, perimenopausal women had a decline in serum IGF-I 1 yr after menopause with an increase in bone turnover markers (6). Frystyk et al. (13) demonstrated that total IGF-I was independent of body mass index (BMI), whereas IGF-II and IGFBP-3 both increased with increasing BMI. BMI per se is a predictor of high BMD (14) . Furthermore, excessive alcohol intake, malnutrition, and liver disease reduce serum IGF-I levels in vivo (8) .
In combination, these findings demonstrate a very complex interaction among age, endogenous estrogen and GH secretion, serum levels of IGFs, BMD, and various confounding factors. Increasing age is associated with a decline in GH secretion and BMD. GH deficiency lowers IGFs (15) , which, in turn, increases after the administration of GH (15) . The decline in IGF-I in postmenopausal women observed by Nasu et al. (6) in a cross-sectional study may at least in part be linked to the known age-related decrease in IGF-I (4).
The aim of the present study was to investigate the effects of estrogen on bone mass and IGFs in perimenopausal women in both a cross-sectional and a longitudinal design. We measured relations among IGFs, BMD, and serum estradiol in untreated perimenopausal women and changes in IGF-I; IGF-II; IGFBP-3; BMD of lumbar spine, femoral neck, and ultradistal forearm; and biochemical markers of bone turnover over a period of 5 yr in perimenopausal women who were allocated to hormone replacement therapy (HRT), or not. Several variables were considered for the analysis to control for potential confounders, as indicated above (16) .
Materials and Methods
The Danish Osteoporosis Prevention Study is a prospective, partly randomized, pragmatic multicenter study on fracture prevention in postmenopausal women through the use of HRT. The study was approved by the regional ethics committee (Aarhus County, no. 1990/1821).
Inclusion criteria were 1) women with intact uterus, aged 45-58 yr, and 3-24 months past last menstrual bleeding or experiencing perimenopausal symptoms (including irregular menstruations) combined with elevated serum FSH; and 2) hysterectomized women, aged 45-52 yr, with elevated FSH. Exclusion criteria were 1) metabolic bone diseases, including osteoporosis, defined as nontraumatic vertebral fractures on x-ray; 2) current estrogen use or estrogen use within the past 3 months; 3) current or past treatment with glucocorticoids for more than 6 months; 4) current or past malignancy; 5) newly diagnosed or uncontrolled chronic disease; or 6) alcohol or drug addiction.
The present cross-sectional study included 595 women attending 1 of the 4 Danish Osteoporosis Prevention Study centers. Of the 525 women attending the 5-yr follow-up visit, a subgroup of 110 randomly selected subjects (46 who had been continuously receiving the same type of HRT and 64 who had not received any type of HRT) were used to study longitudinal changes in serum IGF-I, IGF-II, and IGFBP-3 during HRT. None of these 110 women was taking any other medication.
Women with intact uteri received oral estradiol (2 mg/day) for the first 12 days of each 28-day cycle, estradiol (2 mg/day) and norethisterone acetate (1 mg/day) for the following 10 days, and estradiol (1 mg/day) for the last 6 days (Trisekvens, Novo Nordisk A/S, Glostrup, Denmark). Hysterectomized women received oral continuous estradiol (2 mg/day; Estrofem, Novo Nordisk).
At inclusion and after 5 yr, bone mineral content and BMD were measured in the lumbar spine (L2-L4), the femoral neck, and the ultradistal part of the nondominant forearm by Hologic DEXA scanners (Hologic, Inc., Waltham, MA) in all participants. At inclusion, measurements were performed by a 1000/w scanner, and at 5 yr, they were made by a 2000/w scanner. Cross-calibration was insured through the use of double measurements and a common phantom, as described in detail by Abrahamsen et al. (17) . Precision for BMD was 1.5% for the lumbar spine, 2.1% for the femoral neck, and 1.9% for the ultradistal forearm. These figures included cross-over calibration, change of hardware, change of technicians, and long term stability. Long term stability was high, with changes of less than 0.2%/yr (17) .
At inclusion and after 5 yr, serum albumin, serum albumin-adjusted calcium, serum total alkaline phosphatase, and were measured by standard laboratory methods in all participants. Urinary hydroxyproline (OHP) was measured by Hypronosticon (Organon Teknika, Holland) on a low collagen diet in a morning spot urine (second void). Urinary creatinine was measured by routine laboratory methods.
Serum levels of IGF-I, IGF-II, IGFBP-3, and intact PTH were measured at inclusion in all 595 subjects and in the subgroup of 110 subjects at 5 yr. Serum IGF-I and IGF-II were measured as previously described in detail (18) . Acid-ethanol extracts were devoided of IGFBPs as assessed by Western ligand blot and immunoassays (IGFBP-1, -2, and -3), and results were identical to those obtained by acid-gel chromatography. Intraassay coefficients of variation (CVs) were less than 5%, and interassay CVs were less than 10%. The obtained specificities and sensitivities were high, with less than 0.0002% cross-reactivity in heterologous assays with recombinant human proinsulin, and recombinant human insulin cross-reacting less than 0.01% in the IGF-I assay. Serum IGFBP-3 was measured by an immunoradiometric assay (DSL-6600 Active, Diagnostics Systems Laboratories, Inc., Webster, TX), with intra-and interassay CVs of less than 2% and 4%, respectively. Serum intact PTH was measured by DPC Immulite (chemiluminescense) with an interassay CV of 11% and an intraassay CV of 6%. The ratio between IGF-I (or IGF-II) and IGFBP-3 was used as an index of free IGF, as IGF binds to IGFBP-3.
Furthermore, serum levels of estradiol (AutoDELFIA, Wallac OY, Turku, Finland; intraassay CV, 5.2%; interassay CV, 8.5%), osteocalcin [Bone Gla protein (BGP) by RIA (19) ; intraassay CV, 5%; interassay CV, 10%], and bone-specific alkaline phosphatase [BAP by lectin precipitation (19) ; intraassay CV, 8%; interassay CV, 25%] were measured at inclusion in all participants. Moreover, it was registered at inclusion whether the woman was a smoker or consumed alcohol on a daily basis. Family history of fractures and her daily intake of coffee and tea were also noted. Finally, the intake of calcium and vitamin D was recorded using a diet history method by a clinical dietitian. The CV for intake of calcium from one measurement to the next was 15%, and for vitamin D intake it was 28%.
Statistics
Normal distribution was ensured through logarithmic transformation of skewed parameters (serum estradiol, total alkaline phosphatase, IGF-I, IGF-II, IGFBP-3, and OHP). Groups were compared by t test for two samples and by paired t test when appropriate. Correlations with BMD were tested by multiple stepwise linear regression, with age, BMI, intake of alcohol, current smoking, BAP, BGP, urinary OHP, serum estradiol, serum PTH, serum IGF-I, serum IGF-II, and serum IGFBP-3 as independent variables. Treatment effect was included in the stepwise multiple linear regression in the analysis of changes from baseline to 5 yr. Bivariate correlations were examined using Pearson's correlation coefficient. Median, mean, sd, and sd of the mean were used as descriptive statistics. All calculations were performed using SPSS 6.1.3 for Windows (SPSS, Inc., Chicago, IL). Table 1 gives baseline characteristics for all participants and the subgroup of 110 subjects who had remeasurements of IGFs after 5 yr. Only the number of hysterectomized women and the BAP deviated borderline significantly between the two groups.
Results

Cross-sectional study
Serum IGF-I showed poor, but significant, positive correlations with spinal and ultradistal forearm BMD, but not with femoral neck BMD ( Table 2) . Neither serum IGF-II nor serum IGFBP-3 correlated significantly to regional BMD. At all three sites, BMD correlated inversely to biochemical markers of bone turnover.
Longitudinal study
HRT for 5 yr decreased biochemical markers of bone turnover and maintained BMD at all three sites (Table 3) . HRT reduced serum levels of IGF-I and IGF-II. Serum IGF-I de-creased 21% [double-sided P value (2P) Ͻ 0.001] and IGF-II 7.5% in the HRT-treated group, whereas no changes were observed in the untreated group. Serum IGFBP-3 decreased in treated (20%; 2P Ͻ 0.001) as well as untreated (21%; 2P Ͻ 0.001) subjects without any difference between the groups (P ϭ 0.40). The ratios between IGF-I and IGFBP-3 and between IGF-II and IGFBP-3 increased more in the untreated than in the treated groups in accordance with the observation that total IGFs decreased in the treated women. IGF-I decreased significantly more in hysterectomized women treated with continuous estrogen (n ϭ 6) than in women with intact uterus (n ϭ 40) treated with sequential estrogen plus norethisterone (median change, Ϫ53.5 vs. Ϫ29.5; 2P ϭ 0.043), whereas there were no significant differences for IGF-II (Ϫ100.5 vs. Ϫ198.5; 2P ϭ 0.22) or IGFBP-3 (Ϫ640.5 vs. Ϫ733.0; 2P ϭ 0.58).
Only IGF-I was vaguely correlated to changes in femoral neck and ultradistal forearm BMD (Table 4) . Correlations with IGF-I were positive in the femoral neck and ultradistal forearm, meaning that the decrease in BMD was greater with lower initial serum IGF-I levels. Exclusion of serum BGP, serum BAP, and urinary OHP from the equations did not change the observed correlations. BGP, Serum osteocalcin at inclusion; BMI, body mass index at inclusion; E 2 , serum estradiol at inclusion; IGF-I, IGF-I at inclusion; BAP, serum bone-specific alkaline phosphatase at inclusion; OHP, morning spot urinary hydroxyproline/creatinine ratio at inclusion. Parameters not shown were not significantly associated with the dependent variable.
a Adjusted squared correlation coefficient (i.e. for the spine, the correlation explains 16% of the total variation). b Current daily intake of alcohol (parameter ϭ 1) or not (parameter ϭ 0) at inclusion.
There was no difference between subjects treated with continuous estrogen or sequential estrogen/progestogen (i.e. no difference between hysterectomized and women with intact uterus). Time since menopause did not influence the outcome of the calculations.
Discussion
We present a cross-sectional study on relations among BMD, IGFs, and serum estradiol in perimenopausal women and a follow-up study on long term effects of HRT on BMD and IGFs. During statistical evaluation, special attention was focused on possible confounders.
In the cross-sectional study, we found positive correlations between serum IGF-I and BMD in areas with a high proportion of trabecular bone, such as the spine and the ultradistal forearm, taking known confounders into account. These findings are in accordance with the studies by Nasu et al. (6) and Sugimoto et al. (5) , who reported positive correlations between serum IGF-I and forearm BMD in perimenopausal women and osteoporotic patients. Contrary to Sugimoto et al. (5), we did not find a relationship between serum IGF-I and femoral neck BMD. However, the observed correlations were weak, and only a minor part of the total variation in BMD was explained by the applied models. The poor correlation between IGF-I and BMD may be the reason for the difference between our observations regarding femoral neck BMD and the findings of Sugimoto et al. (5) . Another explanation would be that cross-sectional BMD measurements represent accumulated changes in net bone balance over many years and are only marginally influenced by actual serum IGF-I concentrations. In this setting recent serum IGF-I levels most likely will affect skeletal sites with abundant trabecular bone, such as the spine and the ultradistal forearm, with high bone turnover. Furthermore the production of IGF-I is much larger in the liver than in the bones (8) , indicating that serum levels mostly reflect changes in the liver (8) . The lack of correlation between BMD and serum IGF-II or serum IGFBP-3 may also be explained by the mentioned discrepancy in the time frame between the two types of measurements. The significant inverse relations observed between bone markers (BGP, BAP, and OHP) and BMD at all three measuring sites probably reflect that the rise in bone turnover after menopause is followed by an increase in the remodeling space and over a couple of months by a decrease in the amount of bone (20) . Although cross-sectional spine BMD was linked to IGF-I, there was no correlation between IGF-I and the 5-yr change in spine BMD. A negative association between initial serum estradiol and change in spine BMD was observed. The difference between the cross-sectional and follow-up study could be explained by the hypothesis that IGF-I in estrogen-replete premenopausal women is of significance to peak bone mass (i.e. the amount of bone), whereas the estrogen deficiency plays a larger role in trabecular bone loss in perimenopause (1) . On the other hand, Treatment equals 2, and no treatment equals 1 in the equations. BMI, body mass index at baseline; E 2 , serum estradiol at baseline; IGF-I, IGF-I at baseline; BAP, serum bone-specific alkaline phosphatase at baseline. Parameters not shown were not significantly associated with the dependent variable.
IGF-I was linked to loss of BMD in the femoral neck in the follow-up study, as those with a low initial IGF-I lost more BMD than those with a high initial IGF-I, pointing toward a link between cortical bone turnover and IGF-I (4, 12).
In the 5-yr follow-up study, BMD increased significantly in the HRT group compared to no difference in the lumbar spine and the femoral neck, and was maintained in the ultradistal forearm, as seen in other studies (21) . Furthermore, bone resorption and bone formation decreased in the HRT group, as estimated by total alkaline phosphatase and urinary OHP, which is in accordance with the results of other studies (22) . Serum albumin-adjusted calcium increased in the untreated group compared to that in the HRT group without a significant difference in serum PTH levels between the groups. This supports previous findings that estrogen may influence calcium homeostasis by attenuating the effect of PTH (23) .
Serum levels of IGF-I and IGF-II were both suppressed in the HRT group, whereas identical changes were observed in serum IGFBP-3 in HRT-treated and untreated subjects. It has been observed that oral (but not transdermal) estrogen decreases IGF-I, with a larger decline with increasing basal IGF-I (24). The reason for the reduction in serum total IGF-I and IGF-II during HRT is not fully elucidated. Estrogen inhibits hepatic IGF-I synthesis (8, 24) . Furthermore, estrogen reduces bone turnover, which decreases the number of osteoclasts and osteoblasts (25) . The reduction in bone cell number could inhibit the total skeletal synthesis of IGFs and thereby contribute to the decrease in their serum levels. The estrogen-induced reduction in hepatic IGF-I synthesis may further reduce serum IGF and thus indirectly bone cell activity by decreasing local IGF. However, the positive association between serum IGF-I and changes in femoral neck and ultradistal forearm BMD during HRT may indicate that serum IGF-I modulates bone remodeling by inducing a slightly more positive bone balance per remodeling cycle. Although bone turnover as well as average serum IGF-I diminish during HRT, individuals with the lower baseline IGF-I levels had the larger decrease in BMD. The higher serum total IGF-I levels at the 5-yr follow-up in the untreated subjects may reflect a compensatory regulation to mitigate the accelerated perimenopausal bone loss. However, theoretically this compensation may fail with time due to diminishing IGF-I production with increasing age, an increased need that cannot be met, or an increased resistance to IGFs in the perimenopause.
In conclusion, the cross-sectional study showed a positive correlation between serum IGF-I and BMD of spine and ultradistal forearm. Baseline serum IGF-I correlated positively with changes in BMD in the femoral neck and the ultradistal forearm.
